¹ Nexbody offers a money back guarantee. You may be eligible for a refund or credit if, after strictly following the program as prescribed, you do not have approximately a 10% loss in your body weight within six months. Full compliance with the program requirements—such as follow-ups, proper medication use and adherence, and adherence to all lifestyle recommendations—is necessary to qualify for this guarantee. Please note that participation is subject to change at any time. We reserve the right to cancel the program or update these terms at our discretion, with changes applying to all future requests or claims.
² Some US states require a video consultation before prescription.
* People lost an average of 15% (up to 20%) bodyweight in a 68-week clinical study of Wegovy®., along with a reduced calorie diet and increased exercise. In a 68-week clinical study of Wegovy®, about 1 in 3 adults with obesity or with overweight and weight-related medical problems achieved 20% weight loss. Average weight loss achieved was 15%. Wegovy® is a registered trademark of Novo Nordisk A/S.
Compounded drug products are not approved or evaluated for safety, efficacy, or quality by the FDA.
Wegovy® (semaglutide) and Ozempic® (semaglutide) are not compounded. Wegovy® (semaglutide) is FDA-approved for weight loss. Ozempic® (semaglutide) is FDA-approved for type 2 diabetes treatment but may be prescribed off-label for weight loss at a healthcare provider’s discretion. A healthcare provider may prescribe a compounded drug if determined that it is medically appropriate and necessary for you.